Wuxi Biologics Inc., of Shanghai, said its drug substance and drug product manufacturing facilities at Wuxi city successfully completed a seven-day FDA surveillance inspection by three inspectors for the production of Trogarzo (ibalizumab), the first routine GMP inspection since the product's U.S. approval in March 2018.